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Abstract 
Background:  Huntington’s disease (HD) is caused by an unstable polyglutamine 
(CAG) repeat in the HD gene, whereby a CAG repeat length greater than ~36 leads 
to the disease.  In HD patients, longer repeats correlate with more severe disease 
and earlier death.  This is also seen in R6/2 mice carrying repeat lengths up to ~200.  
Paradoxically, R6/2 mice with repeat lengths >300 have a less aggressive 
phenotype and longer lifespan than those with shorter repeats.  The mechanism 
underlying this phenomenon is unknown. 
Objective: To investigate the consequences of longer repeat lengths on structural 
changes in the brains of R6/2 mice, especially with regard to progressive atrophy. 
Methods: We used longitudinal in vivo magnetic resonance imaging (MRI) and 
spectroscopy (MRS) to compare pathological changes in two strains of R6/2 mice, 
one with a rapidly progressing disease (250 CAG repeats), and the other with a less 
aggressive phenotype (350 CAG repeats). 
Results: We found significant progressive brain atrophy in both 250 and 350 CAG 
repeat mice, as well as changes in metabolites (glutamine/glutamate, choline and 
aspartate).  Although similar in magnitude, atrophy in the brains of 350 CAG R6/2 
mice progressed more slowly than that seen in 250 CAG mice, in line with the milder 
phenotype and longer lifespan.  Interestingly, significant atrophy was detectable in 
350 CAG mice as early as 8-12 weeks of age, although behavioural abnormalities in 
these mice are not apparent before 25-30 weeks.  This finding fits well with human 
data from the PREDICT-HD and TRACK-HD project, where reductions in brain 
volume were found 10 years in advance of the onset of symptoms. 
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Conclusions: The similar brain atrophy with a mismatch between onset of brain 
atrophy and behavioural phenotype in HD mice with 350 repeats will make this 
mouse particularly useful for modelling early stages of HD pathology. 
 
Keywords: MRI; MRS; tensor-based morphometry; neurodegenerative disease; 
trinucleotide repeat disorders  
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Introduction 
Huntington’s disease is a fatal, progressive neurodegenerative disorder caused by 
an unstable polyglutamine (CAG) expansion in the gene coding for the protein 
huntingtin.  It is characterised by motor dysfunction, notably chorea, as well as 
cognitive, psychiatric and sleep abnormalities.  Death typically occurs 12-15 years 
from the first symptoms [1].  HD pathology is characterised by striatal and cortical 
neurodegeneration that is accompanied by the presence of aggregates of mutant 
huntingtin.  These aggregates have been found in the nucleus and cytoplasm of both 
humans [2] and mouse models of HD [3, 4].  The precise role of the inclusions in 
disease development has yet to be resolved. 
The expanded CAG repeat that causes HD is inherently unstable.  In both HD 
patients and mouse models, somatic variation in CAG repeat number affects both 
age at onset and severity of the disease symptoms.  An expansion of 35-37 CAG 
repeats is sufficient to cause HD [5], and longer repeats correlate with earlier age at 
onset of symptoms [6].  However, variability in age of onset is only partly explained 
by the number of CAG repeats, indicating that other factors are involved [7].  It has 
been suggested that in HD patients’ brains, somatic CAG repeat expansion occurs 
until the repeat length reaches a pathological threshold [8].  Therefore, the age of 
onset of HD is dependent upon both the initial length of the CAG repeat, and the 
time it takes for the unstable expansions to reach the toxic threshold.  This fits with 
evidence from studies showing that individuals carrying HD gene mutations are 
overtly neurologically normal until phenoconversion [9, 10].  Even so, results from 
the PREDICT-HD and TRACK-HD initiative show that brain volume loss can be 
detected up to 10 years before symptoms become manifest, suggesting a long-term, 
insidious, process of neuronal loss that only gradually produces any clinical signs 
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[11-14].  However, evidence is accumulating to show that subtle cognitive 
impairment may also be present in HD patients for some years before diagnosis, 
suggesting that the mismatch between onset of brain changes and detection of 
symptoms may be partly due to incomplete diagnostic criteria [15-17]. 
Most mouse models of HD have, by comparison with humans, very long CAG 
repeat lengths (typically in the range 110-250).  This is well-recognised in the field to 
be a caveat to the appropriateness of the models.  However, the need for greater 
initial repeat lengths in mice may be explained by the Kaplan model [8], which 
predicts that unstable expansions need to reach a toxic threshold of ~115 CAGs 
before pathology is seen.  The life span of a mouse (approximately 2 years) may be 
insufficient to allow a pathology-inducing expansion to be reached from a short 
inherited CAG repeat length in the range that causes disease in humans. 
We have previously reported that there are considerable age differences in the 
onset of abnormal phenotype in the R6/2 transgenic mouse model of HD, with the 
relationship between age and CAG repeat length being U-shaped.  As the number of 
CAG repeats increases past 200, so does life span [18].  Furthermore, the timing of 
appearance of the classically described neuronal intranuclear inclusions (NII) [19] is 
delayed in mice with >300 CAG repeats [18].  These findings were similar to those of 
Dragatsis and colleagues, who found an extended lifespan in mice carrying 300-400 
repeats [20].  The idea that longer CAG repeats cause disease with a slower 
trajectory has also been supported by electrophysiological studies [21]. 
We were interested in investigating the consequences of longer repeat lengths 
on structural changes in the brains of R6/2 mice, especially with regard to the 
progressive atrophy that characterises HD.  We used a mixed longitudinal and cross-
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sectional experimental design to compare structural and biochemical changes in 
lines of R6/2 mice carrying 250 or 350 CAG repeats using in vivo high-resolution 
magnetic resonance imaging (MRI) and spectroscopy (MRS).  The advantage of this 
non-invasive method is that a detailed trajectory of morphological changes can be 
monitored longitudinally without the need to sacrifice large numbers of animals at 
each time point.  Automated voxel-based morphometry has proved a sensitive 
method for identifying morphological differences in mouse models of HD both in vivo 
[22] and ex vivo [23]. 
 
Materials and Methods 
Mice 
All procedures were conducted in accordance with the UK Animals (Scientific 
Procedures) Act 1986, and were approved by the University of Cambridge Animal 
Welfare and Ethical Review Board. 
Mice were taken from colonies of R6/2 mice established in the University of 
Cambridge, and maintained by backcrossing onto CBA x C57BL6 F1 female mice.  
Methods for the genotyping of these mice, and details of the animal husbandry, have 
been described previously [3, 24].  Briefly, mice were housed in single-sex, single-
genotype groups of 3-4 at 21-23°C with humidity of 55 ± 10%.  Lowered waterspouts 
were provided for ad libitum access to water and standard dry laboratory food was 
given.  A supplementary feed (of mash made by soaking 100g dry food in 230 ml of 
filtered tap water until pellets were soft and fully expanded) was given each morning 
and evening.  Enrichment was provided by the addition of plastic houses, cardboard 
tubes and chew blocks to the cages.  Genotyping and CAG repeat length 
measurement were carried out by Laragen (Los Angeles, CA, USA).  We selected 
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two groups of transgenic mice (hereafter called 250 CAG and 350 CAG), with CAG 
repeat lengths of either 253 ± 2 (mean ± SEM) or 354 ±3 respectively, as determined 
by GeneMapper. 
We used 26 R6/2 250 CAG mice and 25 R6/2 350 CAG mice, with 35 age-
matched wildtype (WT) mice as control mice.  Scanning took place at 3 week 
intervals, when the mice were aged between 8-21 weeks (250 CAG), or 8-33 weeks 
(350 CAG).  At each time point, scanning the entire cohort of mice took 
approximately 3 weeks, so data were collated in ~3 week blocks (8-12, 12-15, 15-18, 
18-21, 21-24, 24-27, 27-30, 30-33 weeks). 
Image acquisition 
Mice were anaesthetised with isoflurane (1-2% in 1l/min O2).  Respiration rates were 
measured using a pressure-sensor (SA Instruments, Stony Brook, NY, USA).  Depth 
of anaesthesia was adjusted according to the respiration rate to maintain a 
consistent level between mice.  Body temperature was measured with a rectal probe 
and maintained in the normal range using a heated flowing-water blanket.  
Structural Imaging 
Mice were scanned at 4.7T using a Bruker BioSpec 47/40 system (Bruker Inc., 
Ettlingen, Germany).  An actively-decoupled birdcage transmitter (model T5346) was 
used for excitation, and the manufacturer-provided quadrature mouse head surface 
coil (model T9788) was used for signal reception.  Structural imaging was achieved 
with a rapid acquisition with relaxation enhancement (RARE) sequence (scan 
parameters: repetition time 3.5s, effective echo time 32ms, bandwidth 40 kHz, echo 
train length 12, field of view 25.6×19.2×10.0mm3, matrix 256×192×100).  The final 
resolution was 100µm isotropic, and images were acquired in 1 hour 33 minutes.  
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Magnetic resonance spectroscopy 
Following structural imaging, a point-resolved selective spectroscopy (PRESS) voxel 
was positioned at the level of the left caudate putamen.  The voxel extended 2mm in 
each direction (8µl) and was acquired with 128 transients with a repetition time of 
2.5s and echo time 20ms.  Water suppression was achieved with the variable power 
and optimized relaxation (VAPOR) scheme with manually-adjusted pulse power and 
localised shimming was performed using the manufacturer-provided FASTMAP 
routine with a 4mm cubic voxel centred on the smaller PRESS region.  Outer volume 
suppression was enabled and a navigator signal was acquired for retrospective 
frequency locking.  
 
MR data analysis 
Tensor-based morphometry  
Tensor-based morphometry (TBM) was performed using SPM8 (Wellcome Trust 
Centre for Neuroimaging, UCL) with the DARTEL registration software [25] modified 
for mice using the SPMMouse toolbox. 
Images were aligned manually with the mouse template created during our 
previous voxel-based morphometry study [26] and segmented using unified 
segmentation [27].  DARTEL was used with the settings we have described 
previously [22] to produce maps of local volume change (Jacobian determinants).  
We used the maps in three different ways.  Firstly, we compared separately the 
local volume differences from R6/2 250 CAG mice or R6/2 350 CAG mice with those 
of WT mice at the age of 12-15 weeks, and also compared male with female mice in 
all three groups.  Determinant maps were smoothed by a 400µm isotropic Gaussian 
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smoothing kernel.  To control for the type I errors expected due to multiple 
comparisons, a false-discovery rate of q < 0.05 was used [28].  This correction 
means one can expect that, on average, 5% of the findings reported as significant 
will be false positives.  Secondly, for visual comparison, we produced maps showing 
the mean difference between the Jacobian determinant of WT and R6/2 mice of 
each genotype at 8-12 weeks and for each 3 week block thereafter, as long as at 
least 4 mice survived per group (until 21 weeks in 250 CAG mice and 33 weeks in 
350 CAG mice).  Thirdly, we extracted mean determinants within regions of interest 
(ROI) [29] for each mouse at each time point to compare trajectories of change over 
time for each genotype.  We measured the caudate putamen, cerebral cortex, lateral 
ventricles, internal capsule, hippocampal formation and amygdaloid nucleus.  To 
compare rates of change, linear regression lines were calculated using Matlab 
R2014 (MathWorks, Cambridge, MA, USA) and statistical significance of regression 
slopes was assessed using permutation testing, preserving animal age though 
randomly permuting genotype labels.  We first looked for sex differences in rates of 
volume change of the localised structures, and where none were present, data from 
male and female mice were combined for further analysis as described above. 
Spectroscopy analysis 
Spectra were analysed using basis functions with LCModel version 6.3 [30] from 4.0-
0.2ppm using the 200MHz gamma PRESS basis set.  For more accurate 
measurements, we followed the guidelines of the software and measured the sum of 
glycerophosphocholine and phosphocholine (hereafter referred to as choline and 
abbreviated to cho), the sum of n-acetylaspartate and n-acetylaspartylglutatamate 
(hereafter referred to as aspartate, abbreviated to NAA), glutamate and glutamine 
(hereafter referred to as total glutamine-glutamate, abbreviated to Glx).  In addition, 
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we measured the amino acid taurine.  Metabolites were only considered for analysis 
where the standard deviation of modelling fits (Cramér-Rao lower bound) was lower 
than 20% in more than 90% of spectra acquired.  For normalisation, metabolites 
were considered as ratios to the sum of creatine and phosphocreatine for each 
voxel.  There is a caveat to our spectroscopy data, which is that the use of total 
creatine and phosphocreatine levels to normalise metabolite values could lead to 
confounded values if levels of creatine itself change.  It is possible to use water 
levels as an alternative [31].  However, there is also a potential confound with this 
technique.  Given the atrophy of the striatum, and the increased ventricular volume 
in the region of the 1H-MRS voxel, it is possible that all metabolites would appear to 
be decreased in concentration as the visible water signal increases.  Therefore, 
there are disadvantages to both techniques, so we chose the one that was less 
affected by physical changes in the brain. 
 
Results  
Life spans of R6/2 mice were similar to those of our previous reports, with R6/2 250 
CAG mice reaching end stage at 22-26 weeks and R6/2 350 CAG mice reaching end 
stage at 30-33 weeks.  A total of 148 scans were acquired (37 from R6/2 250 mice, 
49 from R6/2 350 CAG mice and 62 from WT control mice).  Figure 1 shows MR 
images of end-stage morphology for R6/2 250 (Figure 1D-F) and 350 (Figure 1G-I) 
CAG mice (25 and 32 weeks respectively), with a 40 week old WT mouse (Figure 
1A-C) used for comparison.  Inspection of the images shows that cortical atrophy is 
particularly apparent in the R6/2 250 CAG mice, especially in the frontal cortex.  Both 
groups of R6/2 mice showed enlarged ventricles with reduced striatal volume 
compared to WT controls.  
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We used TBM to look for differences between the brains of male and female 
mice at 12-15 week.  No significant sex differences were found, even when the 
threshold for statistical significance was raised to exploratory levels (controlling the 
false-discovery rate at p < 0.25; data not shown).  Since there were no sex 
differences, we combined male and female data in further analyses.  TBM analysis 
of brains of mice aged 12-15 weeks showed widespread reductions of volume in 
both lines of R6/2 mice compared to WT mice.  R6/2 250 CAG mice showed more 
regions of significantly lower volume than were seen in R6/2 350 CAG mice (Figure 
2).The changes were predominantly in grey matter structures in both groups of mice.  
In R6/2 250 CAG mice(Figure 2A), several of the basal ganglia were reduced in 
volume, with highly significant clusters seen in the caudate putamen and substantia 
nigra, although no changes were detected in lateral parts of the globus pallidus.  The 
cortex was also widely affected, with the most significant effects being seen in the 
frontal cortex and parietal cortices, to a lesser extent the temporal cortex, and with 
some apparent sparing of superior aspects to the occipital cortex.  The hippocampal 
formation, and in particular the dentate gyrus, was also reduced in volume. The 
central grey matter was also affected.  The cerebellum showed reduced volume, in 
particular the fifth and sixth lobes, while the brain stem and medulla were largely 
spared (Figure 2A).  At 12-15 weeks, atrophy in 350 CAG mice (Figure 2B) was less 
wide-spread than in the 250 CAG mice.  Significant changes were seen mainly in the 
striatum, sensorimotor cortex, amygdala, and hippocampal formation.  The 
differences in the hippocampus were focal, and centred on the CA2 subfield and 
dentate gyrus, compared to the more global changes seen in the hippocampal 
formation of 250 CAG mice. 
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Figure 3 shows the measured difference in local volume over time at each part in 
the brain in R6/2 mice relative to WT mice.  For 250 CAG mice, the substantial 
reductions in brain volume seen at 8-12 weeks increased over time, with 
corresponding enlargement of the ventricles.  Expansion of the lateral ventricles 
mirrored atrophy of the striatum.  Interestingly, significant atrophy was also seen in 
350 CAG mice at 8-12 weeks, even though their behavioural phenotype is not 
evident until 25-30 weeks of age.  Volume changes in 350 CAG mice at all ages 
examined up to end stage were less severe than they were in 250 CAG mice.  There 
appears to be a time lag of approximately 10 weeks between the timing of 
appearance of a similar level of volume reduction in 250 and 350 CAG mice.  For an 
example, compare damage at 8-12 weeks in 250 CAG mice with that at 18-21 weeks 
in 350 CAG mice (Figure 3).  Notably, brain atrophy in 350 CAG mice never reached 
the final level of severity that was seen in 250 CAG mice, although both 250 and 350 
CAG mice all died prematurely of the disease.  The use of TBM in this study enabled 
us to detect changes in tissues that are further from grey and white matter 
boundaries than would be possible using VBM alone as in our previous study [26].  
TBM showed that atrophy in the R6/2 cortex is not generalised, but rather is more 
prominent within discrete layers of the cortex in R6/2 mice, with the peripheral layers 
being least affected (Figure 4). 
 
Longitudinal ROI measurements  
The analysis for sex differences showed a greater rate of volume increase in the 
lateral ventricles for CAG 350 female mice when compared to male mice (p < 0.002; 
Supplementary Figure 1).  There were no other significant differences in the rate of 
change of structures by sex.  Significant longitudinal atrophy (p < 2×10-5) was seen 
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in the cortex (Figure 5A), caudate putamen (Figure 5B), amygdaloid nucleus (Figure 
5D), hippocampal formation (Figure 5E) and cerebellum (Figure 5G) in both the 250 
and 350 CAG repeat R6/2 mice.  As expected, the lateral ventricles significantly 
increased in volume in all R6/2 mice (p < 2×10-5, Figure 5C).  The internal capsule 
was unaffected (Figure 5F).  When comparing data between R6/2 lines, a significant 
difference in rate of overall atrophy was seen for the cortex (p < 0.002, Figure 5A), 
caudate (p<1×10-5, Figure 5B), amygdaloid nucleus (p<2×10-5, Figure 5D), 
hippocampal formation (p < 1×10-5, Figure 5E), and cerebellum (p < 1×10-5, Figure 
5G), with atrophy in the 350 CAG mice being much slower.  No significant changes 
were seen in the internal capsule (p = 0.3, Figure 5F). 
 
Metabolites 
We measured the levels of four metabolites (NAA, Glx, cho, taurine), all of which 
showed age-dependent changes in one or both lines of R6/2 mice.  Levels of the 
neuronal marker NAA decreased significantly with age in both R6/2 250 (p < 0.0002) 
and 350 CAG mice (p<0.01) when compared to WT mice (Figure 6A). Glx 
concentrations decreased with age faster in R6/2 than WT mice (250 CAG, p < 0.006 
and 350 CAG, p < 0.002, Figure 6C).  Compared to WT mice, taurine increased 
significantly over time in both 250 and 350 CAG mice (p < 0.01 and p < 0.04 
respectively, Figure 6D).  Interestingly, a significant decrease in choline 
concentration (p < 0.05) was seen in the R6/2 350 CAG mice but not the 250 CAG 
mice (Figure 6B).Comparing the R6/2 250 CAG and 350 CAG mice directly, 
significant differences were seen only for choline (p < 0.01) (Figure 6B). 
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To summarise our results, the MRI data show that structural and biochemical 
aspects of the neurodegenerative phenotype are similar in mice with 250 and 350 
CAG repeats.  Atrophy begins in the frontal cortex, sensorimotor cortex, caudate and 
amygdaloid nucleus for both 250 and 350 CAG repeat mice, but progression of the 
atrophy is much slower in 350 CAG repeat mice.  These findings are consistent with 
the slower progression of the behavioural phenotype and extended life span of CAG 
350 mice compared to 250 CAG mice [18]. 
 
Discussion 
The unfavourable prognosis in HD patients and animal models in relation to longer 
CAG repeat lengths is widely reported [6, 32, 33].  However, evidence is 
accumulating to indicate that this is not a straightforward relationship, and that 
mouse models of HD with CAG repeat lengths over 200 have an ameliorated 
phenotype compared to mice with fewer repeats [18, 20, 21].  In this study, we used 
high resolution MRI, MRS and automated whole brain analysis to examine the 
development of neuronal atrophy in R6/2 mice with markedly different CAG repeat 
lengths, duration of disease and behavioural phenotypes.  We compared directly 
R6/2 mice with 250 CAG repeats (that has a rapidly progressing disease) and 350 
CAG repeats (that has an ameliorated phenotype and longer lifespan [18]).  We 
found widespread brain atrophy in R6/2 250 CAG mice from 8 weeks of age, 
approximately 4 weeks before overt physical signs but after cognitive [34] and 
electrophysiological [20] changes are detectable.  In 350 CAG mice, atrophy was 
also detectable at 8-12 weeks of age.  This was an interesting result, as it anticipates 
the behavioural phenotype by at least 15 weeks [18].  However, it fits well with 
clinical data showing brain volume loss in HD patients some years before the onset 
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of symptoms [11, 12].  By 30-33 weeks of age the atrophy in the brains of 350 CAG 
mice was widespread and substantial, although the rate of atrophy throughout the 
mice’s lifespan was very much slower and did not reach the severity of that seen in 
250 CAG mice, even when the mice were at the end-stage of their phenotype.  The 
significance of this is not clear, although it makes it unlikely that brain atrophy is the 
cause of either behavioural changes or death in R6/2 mice.  It is interesting to note 
that R6/2 mice with even longer repeat lengths (550 CAG) also show profound 
neuronal loss in the striatum and cortex, yet have a normal mouse lifespan 
(unpublished data, C. Kielar and A.J. Morton).  Our data suggest that there is a 
similar morphological trajectory but a different time course underlying the atrophy in 
the 250 and 350 CAG R6/2 mice.  That is, the disease begins in the same place and 
progresses similarly in the two lines of mice.  Previous characterisations of allelic 
series of R6/2 mice carrying much longer CAG repeat lengths than those seen in 
typical HD patients have used histological assessment [18, 20] or electrophysiology 
[21].  Each of these studies found that the correlation of CAG repeat length with 
worsening disease trajectories is overturned after a critical value: at some point the 
mice carrying more polyglutamine repeats in their transgenic HD gene have an 
increased life span and show a delayed phenotype of HD-like symptoms.  Our 
current data fit well with these previous studies.  For completeness, it would have 
been interesting to look at mice with shorter CAG repeats (e.g. 110 CAGs).  
However, these mice have a very aggressive phenotype and very short lifespan, 
which makes longitudinal scanning with multiple anaesthesia sessions difficult. 
We found no sex differences in rate of changes of brain structures in the 250 
CAG mice, in accordance with our previous studies [22, 26, 29].  However, we did 
find that in the 350 CAG mice, lateral ventricles increased in size faster in female 
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than male TG mice.  This may be another manifestation of the differences in time 
course of changes between the two strains, i.e. there may be sex differences in the 
250 CAG mice but they are so short-lived that they did not show up on our analysis.  
It has been reported that there are sex differences in brain volumes in R6/2 mice 
with 210 CAG repeats [35].  The difference in results between our current study and 
that of Rattray et al. may be explained by differences in methodology –we used an 
automated analysis (TBM), while the Rattray study used manual volumetry.  It is 
interesting to note that while we found no absolute differences in brain structures 
between male and female CAG 350 mice at the 12-15 week timepoint, we did detect 
differences between the sexes in the rate of change.  This emphasises the value of a 
longitudinal analysis, which can detect changes that might otherwise be missed. 
We have referred to the reduction in brain volumes we found in R6/2 mice as 
atrophy.  However, it has been suggested that mutant huntingtin can also cause 
developmental dysfunction that contributes to neurodegeneration [36].  A study using 
BACHD mice has led to the proposition that HD pathology has two components, one 
developmental and the other resulting from the long-term toxic effects of mutant 
huntingtin [37].  While BACHD mice have a different genetic construct to R6/2 mice, 
we cannot rule out the possibility that at least some of the volume reduction we have 
observed is due to a developmental process. 
Our MRS data showed progressive declines in NAA, glutamine/glutamate and an 
increase in taurine in both lines of R6/2 mice.  As was seen with structural MRI, the 
rate of change was slower in 350 than 250 CAG mice.  Decreased NAA has also 
been reported in HD patients [38-40], and140-150 CAG R6/2 mice [41, 42].  Since 
levels of NAA may reflect the functional status of neuronal mitochondria [43], the 
reduced levels of NAA we found in the R6/2 mice may reflect neuronal dysfunction.  
Page	17	of	34	
Our findings of reduced glutamine/glutamate levels in both 250 and 350 CAG R6/2 
mice reflect data from HD patients [44, 45], and are consistent with the reduced 
glutamatergic signalling and receptor binding seen in symptomatic animals and 
humans [46, 47].  Increased taurine levels have been reported previously in 150 
CAG R6/2 mice [42], zQ175 knock-in mice [31], and the APP mouse model of 
Alzheimer’s disease [48].  Taurine protects against oxidative stress in the 3-NP 
model of HD [49], is associated with apoptosis in brain tumours [50], and helps 
regulate brain volume [51, 52].  It is possible that the elevated levels seen in models 
of HD (including those used here) are a homeostatic response to the widespread 
apoptosis and atrophy resulting from the phenotype.  The reduction in choline levels 
that we found in 350 CAG R6/2 mice reflects data from 200 CAG R6/2 mice [53] and 
from HD patients, where a decrease in choline has been reported in the frontal 
cortex and putamen [40, 54]).  It has been suggested that cellular dysfunction 
preceding death may lead to reduced concentrations of choline [54].  This being the 
case, it is interesting that choline levels were lower in the 350 CAG but not the 250 
CAG R6/2 mice.  This may suggest a compensatory mechanism in the more severe 
form of the disease, or that the 250 CAG mice died before choline levels changed.  
Either way, it would be interesting to study this further. 
Taken together, our data show that although the overall pattern of atrophy is 
similar in the two strains, the underlying pathology has an extended timecourse in 
350 CAG mice, which may contribute to their longer lifespan.  It has been proposed 
that the aggressive phenotype in R6/2 mice with shorter repeats may be due to 
accumulation of mutant protein in the nucleus, and that the larger protein made in 
mice with longer repeats may be too big to enter the nucleus, leading to an 
amelioration of the phenotype [20].  Unpublished work in 550 CAG mice (C. Kielar & 
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A.J. Morton) showed the presence of many large extranuclear inclusions but few 
neuronal inclusions in these mice, adding weight to the theory that mutant huntingtin 
produced by very long CAG repeats may not enter the nucleus.  Cell death still 
occurs, however, suggesting that the mechanism of toxicity does not depend on the 
formation or nuclear localisation of neuronal inclusions.  A second possible 
mechanism comes from the study by Duzdevich et al., who found that in 350 CAG 
repeat mice, the proportion of DNA molecules with unusual structures was 
approximately double that seen in 250 CAG mice [24].  They suggested that these 
abnormal structures found in DNA with very long CAG repeats may reduce 
transcription of the transgene [24].  It is possible, therefore, that as repeat lengths 
increase, production of mutant huntingtin decreases, leading to prolonged cell 
survival compared to cells containing DNA with shorter CAG repeats. 
Our current study builds on our previous examination of ex vivo 18 week old 
R6/2 mice [26].  In this study we have greater sensitivity due to (a) improved in vivo 
contrast and preserved overall brain shape (without the damage or variability 
introduced by extraction of the brain from the skull and consequent loss of 
cerebrospinal fluid pressure post mortem) and (b) the fact that we used TBM as 
opposed to the voxel-based morphometry (VBM) we used in our previous work.  The 
methodological advantage of TBM is that local volume changes are used to compare 
morphology, instead of modulated grey and white matter volume scores [27, 55].  
This avoids potential errors that may be caused by changes in the chemical 
properties of tissues within each voxel.  For example, changes in water content 
affect signal intensity.  Local changes in water content, which can occur as a result 
of pathological processes, could lead to voxels that would be classified by VBM as 
white matter in WT brain to be misclassified as grey matter in a transgenic brain.  
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Furthermore, and importantly for small brains such as those of mice, TBM is more 
sensitive than VBM to changes that are further from grey and white matter 
boundaries.  This increased sensitivity allowed us to identify atrophy within layers of 
the cortex in R6/2 mice, while our earlier VBM study restricted our findings to atrophy 
of the cortex as a whole [26]. 
 
Conclusion 
We have compared, for the first time using in vivo longitudinal volumetric and 
spectroscopic measures, two allelic strains of R6/2 mice, one with 250 and one with 
350 CAG repeats.  Although the 350 CAG mice display a delayed and prolonged 
behavioural phenotype, and live longer than those mice with 250 CAG repeats, early 
atrophy was seen in the brains of these mice, with atrophy preceding behavioural 
changes by at least 10 weeks in the 350 CAG repeat mice.  The pattern of 
progressive structural changes seen was similar in both lines of mice, with atrophy 
beginning in the frontal cortex, sensorimotor cortex and then progressing to other 
brain regions.  MRS data also show a similar pattern of changes in 250 and 350 
CAG mice, with reductions in levels of NAA and glutamine/glutamate and increases 
in taurine levels in both strains of transgenic mice.  The slower MRI and MRS 
phenotype in mice with 350 CAG repeats confirms the toxicity mismatch, since the 
350 CAG mice develop significant brain pathology in the absence of a behavioural 
phenotype.  We suggest that the 350 CAG R6/2 mouse will be an excellent model for 
studying the expanded CAG repeat-dependent mechanisms of toxicity in HD.  The 
similar but slower rate of disease progression and extended lifespan, relative to the 
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250 CAG mice, also provides a long window of opportunity in which to evaluate both 
pathological mechanisms and potential therapies. 
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Figure legends 
 
Figure 1.  Sagittal, coronal and horizontal MR images comparing examples of 
WT mice at 40 weeks (A-C), R6/2 CAG 250 mice at 25 weeks (D-F), and R6/2 
CAG 350 mice at 32 weeks (G-I).  At the end stage of their disease there is 
pronounced atrophy in the cortex of 250 CAG mice (arrows), and in the caudate of 
250 and 350 CAG mice, leading to enlarged ventricles (asterisks).  White lines 
indicate the relative positions of the three slices. 
Figure 2.  Serial coronal slices from R6/2 250 CAG repeat mice (A) and 350 
CAG repeat mice (B) at 12-15 weeks of age, showing TBM comparisons of local 
volume relative to WT mice.  Statistical colour map of brain atrophy of slices from 
age-matched R6/2 mice shows that atrophy is more severe in mice with 250 CAG 
repeats than it is in mice with 350 CAG repeats.  Slices are 400µm apart, and are 
orientated from anterior (top left) to posterior (bottom right).  The colour bar shows 
Student’s t-score with 24 degrees of freedom. 
Figure 3.  Serial coronal slices from R6/2 250 CAG and 350 CAG repeat mice, 
showing average volume differences relative to WT mice over time.  
Progression of atrophy is slower in 350 CAG repeat mice, and less pronounced at 
end-stage in 350 CAG mice than it is in 250 CAG repeat mice.  Note that equivalent 
levels of atrophy take around 10 weeks longer to appear in 350 CAG than 250 CAG 
mice (for example, compare changes at 18-21 weeks in 350 CAG mice with that at 
8-12 weeks in 250 CAG mice). 
Figure 4.  Serial coronal slices from R6/2 250 CAG repeat mice (A-D) and 350 
CAG repeat mice (E-H) at 12-15 weeks of age, showing layering of cortical 
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atrophy.  Slices from Figure 2 shown at higher magnification demonstrate that in the 
more caudal aspects of the cortex in R6/2 250 CAG repeat mice in particular, deeper 
layers show greater atrophy than the superficial layers (C-D).  Atrophy in the cortex 
of 350 CAG mice at 12-15 weeks is confined to deep layers (E-F). 
Figure 5.  Progression of volume change in selected regional brain areas with 
age in WT and R6/2 mice.  Data points are volumes of cortex (A), caudate putamen 
(B), lateral ventricles (C), amygdaloid nucleus (D), hippocampal formation (E), 
internal capsule (F) and cerebellum (G) for all individual mice.  Solid lines show 
robust fits to the data with shaded regions indicating one standard deviation above 
and below the line respectively.  Black lines = WT mice; red lines = R6/2 250 CAG 
mice; blue lines = R6/2 350 CAG mice. 
Figure 6.  Metabolite concentrations (relative to overall creatine + 
phosphocreatine levels), in striatum of WT and R6/2 mice.  Data points show 
relative concentrations of aspartate (A), choline (B), glutamine and glutamate (C) 
and taurine (D) from individual mice.  Solid lines show robust fits to the data with 
shaded regions indicating one standard deviation above and below the line 
respectively.  Black lines: = WT mice; red lines = R6/2 250 CAG mice; blue lines = 
R6/2 350 CAG mice. 
Supplementary Figure 1.  Sex difference in rate of volume change in the lateral 
ventricles with age in WT and R6/2 mice.  Solid lines show robust fits to the data 
with shaded regions indicating one standard deviation above and below the line 
respectively.  Black lines = WT mice; red lines = R6/2 250 CAG mice; blue lines = 
R6/2 350 CAG mice.  Left panel, male mice; right panel, female mice. 
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